FDA Approves New Combination Therapy for Metastatic Prostate Cancer

The U.S. FDA has authorized capivasertib, in conjunction with abiraterone and prednisone, to treat PTEN-deficient metastatic prostate cancer. This marks the first targeted therapy specifically for this aggressive cancer subtype, which typically has poor patient outcomes. The approval was based on Phase III trial data showing a notable reduction in disease progression or death.